Revvity Expands Preeclampsia Screening with SuperFlex System Launch
Event summary
- Revvity launched the CE-IVDR certified SuperFlex prenatal screening system on August 10, 2026.
- The compact immunoassay instrument targets preeclampsia testing in lower-volume labs and clinics.
- System offers affordable entry, operational simplicity, and flexible throughput with results in 14 minutes.
- Initial availability in CE-marked markets, with Asia-Pacific expansion planned for late 2026.
The big picture
Revvity's SuperFlex launch addresses critical gaps in preeclampsia screening access, targeting the growing global burden of maternal health complications. With $2.9 billion in 2025 revenue and a presence in over 160 countries, this strategic move positions Revvity to capture market share in decentralized diagnostic testing. The system's affordability and flexibility could reshape prenatal care workflows, particularly in regions with limited high-throughput lab infrastructure.
What we're watching
- Market Expansion
- The pace at which Revvity can penetrate Asia-Pacific markets with its new prenatal screening solution.
- Competitive Positioning
- How SuperFlex's decentralized testing capabilities will affect competition in the prenatal diagnostics space.
- Regulatory Compliance
- Whether Revvity can maintain its certification advantages as regulatory standards evolve globally.
Related topics